Welcome!

News Feed Item

Vernalis PLC: Announcement of Results for Year Ended 31 Dec 2013

WINNERSH, UNITED KINGDOM -- (Marketwired) -- 04/01/14 --


1 April 2014

LSE: VER

Announcement of Results for the year ended 31 December 2013

Vernalis plc (LSE: VER) today announces its audited results for the year ended 31 December 2013.

Financial Highlights

  • Financial performance ahead of market expectations

  • Revenue was GBP14.1 million (2012: GBP14.6 million)

- Frovatriptan royalty income was up 16 % at GBP6.7 million (2012:
GBP5.7 million) primarily due to a 14% increase in volume of activepharmaceutical ingredient (API) supplied, with underlying in-market sales made by Menarini flat

- Research collaboration income was GBP7.1 million (2012: GBP8.7 million) including GBP2.5 million of milestones payments (2012: GBP2.6 million) allowing our research organisation to remain self-funding

  • Operating costs before exceptional items were GBP19.3 million (2012: GBP18.2 million), up 6% due to preparatory activities for expansion into the US and investment in the NCE pipeline (V158866 and V81444)

  • Pre-exceptional loss for the year was GBP5.6 million (2012: GBP5.2 million) and GBP4.0 million (2012: GBP5.2 million) on a
    post-exceptional basis

  • Cash resources including cash and cash equivalents and held to maturity assets reduced by GBP4.7 million in the year following:

- GBP2.0 million proof-of-concept milestone payment to Tris for CCP-01 and

- GBP0.9 million foreign exchange loss on the conversion of cash held in US dollars into sterling

  • Balance sheet remains strong with GBP76.9 million of cash resources and no debt

Operational Highlights

Cough Cold Commercial Pipeline:

  • CCP-01 proof-of-concept achieved and milestone paid to Tris (March 2013)

  • Successfully completed single and multi-dose pivotal bioavailability studies (November 2013 and February 2014), completing
    the clinical studies required for NDA filing

  • Positive interim six months stability data for CCP-01 has been generated and NDA filing on track for mid-2014

  • Four further programmes in active development at Tris, and we aim to achieve POC on all four of the remaining programmes during 2014

Frovatriptan (marketed) (Migraine):

  • Underlying Menarini sales flat at EUR26.4 million (2012: EUR26.5 million)

  • Menarini outlook for 2014 is for flat underlying sales vs 2013, both in tablet volumes and sales revenue

  • We expect Menarini to reduce stock in 2014 with 2 shipments of API, one in each half of the year

NCE Development Pipeline:

V81444 (CNS diseases)

  • Phase Ib/II POC study initiated (July 2013) with data anticipated in H1 2014

V158866 (Pain)

  • Phase II POC study initiated (April 2013) and progressing well. Of a total of 36 subjects, 16 have completed and a further 4 are enrolled. Data now anticipated around the end of 2014

AUY922 (Cancer)

  • Phase I and Phase II studies in multiple oncology indications including lung and breast continue with Novartis

Tosedostat - CHR2797 (Cancer)

  • Cell Therapeutics reported positive interim results from an investigator-initiated Phase II trial at the 55th American Society of Haematology annual meeting (December 2013)

  • The partial clinical hold on investigator led trials was removed by FDA in January 2014 enabling studies to resume

RPL554

  • Anti-inflammatory study results announced by Verona Pharma (March 2013)

  • Verona announced a successful GBP14 million fundraising in March 2014. Some of the proceeds are intended to be used to develop RPL554 in three clinical studies using a nebulised formulation in patients with severe COPD and additional studies are planned to prepare for a larger Phase IIb study in hospitalised COPD patients. Results are expected in
    2015

Research Collaborations:

  • New collaboration with AKP announced (October 2013) and GBP0.3 million milestone earned (March 2014)

  • First Servier collaboration extended for a further 2 years (March 2013)

  • GBP2.5 million of milestones earned from successful collaboration with Genentech (February and March 2013)

Expected 2014 Newsflow:

  • V81444 (CNS diseases) - Complete Phase Ib/II POC study (Data H1 2014)

  • CCP-01 - Filing of NDA (Mid 2014)

  • Proofs-of-concept on all four remaining programmes in cough cold pipeline (by 2014 year end)

  • V158866 (Pain) - Complete Phase II POC study (Data around 2014 year end)

  • AUY922 (Cancer) - Multiple Phase I and II study results (Novartis) (undisclosed)

  • Tosedostat - CHR2797 (Cancer)- Phase II study results (Chroma) (undisclosed)

  • Achieve milestones under existing collaborations (undisclosed)

  • Secure new research collaborations (undisclosed)

Ian Garland, Chief Executive Officer, commented, "We made significant progress across all three elements of our strategy during 2013 and continued our strong financial and operational performance. Our lead cough cold programme, CCP-01, progressed rapidly achieving proof-of-concept, successfully completing both required pivotal clinical studies and achieving six month accelerated stability. We are on target therefore for an NDA filing in mid-2014. With four further cough cold programmes in development we aim to achieve POC on all four of these programmes in the coming year.

In the NCE pipeline we initiated two POC studies for V81444 and V158866 and expect data from both, during 2014. We also had another positive year in our research business following on from last year's record performance and continue to be self-funding.

The outlook for 2014 and beyond is extremely positive as we get closer to our first NDA filing from the cough cold portfolio and its potential approval in the first half of 2015."

Presentation & Conference Call

Vernalis management will host a presentation at 9.00am (UK) at
Brunswick's offices, 16 Lincoln's Inn Fields, London WC2A 3ED today. It
will also be available via webcast at http://www.vernalis.com/
investor-centre/presentations-and-webcasts and www.cantos.com and via
conference call, which can be joined by dialling: +44 (0) 20 3139 4830,
Passcode #35707904.

Enquiries:

Vernalis plc:
Ian Garland, Chief Executive Officer
+44 (0) 118 938 0015
David Mackney, Chief Financial Officer

Canaccord Genuity Limited (Nominated Adviser):
+44 (0) 20 7523 8350
Lucy Tilley
Dr Julian Feneley
Henry Fitzgerald-O'Connor

Shore Capital (Joint Broker)
+44 (0)20 7408 4090
Bidhi Bhoma
Toby Gibbs

Brunswick Group:
+44 (0) 20 7404 5959
Jon Coles

Click on, or paste the following link into your web browser, to view
the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/6618D_1-2014-3-31.pdf

This information is provided by RNS
The company news service from the London Stock Exchange

END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
An IoT product’s log files speak volumes about what’s happening with your products in the field, pinpointing current and potential issues, and enabling you to predict failures and save millions of dollars in inventory. But until recently, no one knew how to listen. In his session at @ThingsExpo, Dan Gettens, Chief Research Officer at OnProcess, discussed recent research by Massachusetts Institute of Technology and OnProcess Technology, where MIT created a new, breakthrough analytics model for s...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2017 New York. The 20th Cloud Expo and 7th @ThingsExpo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Internet to enable us all to im...
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We are a custom software development, engineering firm. We specialize in cloud applications from helping customers that have on-premise applications migrating to the cloud, to helping customers design brand new apps in the cloud. And we specialize in mobile apps," explained Peter Di Stefano, Vice President of Marketing at Impiger Technologies, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...